Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial.

ABSTRACT:

Background

Major Depressive Disorder (MDD) has been associated with brain-related changes. However, biomarkers have yet to be defined that could "accurately" identify antidepressant-responsive patterns and reduce the trial-and-error process in treatment selection. Cerebral blood perfusion, as measured by Arterial Spin Labelling (ASL), has been used to understand resting-state brain function, detect abnormalities in MDD, and could serve as a marker for treatment selection. As part of a larger trial to identify predictors of treatment outcome, the current investigation aimed to identify perfusion predictors of treatment response in MDD.

Methods

For this secondary analysis, participants include 231 individuals with MDD from the EMBARC study, a randomised, placebo-controlled tri

SUBMITTER: Cooper CM 

PROVIDER: S-EPMC6543260 | biostudies-literature | 2019 Apr

REPOSITORIES: biostudies-literature